Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease

Language
en
Document Type
Article
Issue Date
2022-07-08
First published
2022-07-04
Issue Year
2022
Authors
Mellor, Liliana F
Gago-Lopez, Nuria
Bakiri, Latifa
Schmidt, Felix N
Busse, Björn
Rauber, Simon
Jimenez, Maria
Megías, Diego
Oterino-Soto, Sergio
Sanchez-Prieto, Ricardo
Editor
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism
Abstract

ObjectivesS100A9, an alarmin that can form calprotectin (CP) heterodimers with S100A8, is mainly produced by keratinocytes and innate immune cells. The contribution of keratinocyte-derived S100A9 to psoriasis (Ps) and psoriatic arthritis (PsA) was evaluated using mouse models, and the potential usefulness of S100A9 as a Ps/PsA biomarker was assessed in patient samples.MethodsConditional S100A9 mice were crossed with DKO* mice, an established psoriasis-like mouse model based on inducible epidermal deletion of c-Jun and JunB to achieve additional epidermal deletion of S100A9 (TKO* mice). Psoriatic skin and joint disease were evaluated in DKO* and TKO* by histology, microCT, RNA and proteomic analyses. Furthermore, S100A9 expression was analysed in skin, serum and synovial fluid samples of patients with Ps and PsA.ResultsCompared with DKO* littermates, TKO* mice displayed enhanced skin disease severity, PsA incidence and neutrophil infiltration. Altered epidermal expression of selective pro-inflammatory genes and pathways, increased epidermal phosphorylation of STAT3 and higher circulating TNFα were observed in TKO* mice. In humans, synovial S100A9 levels were higher than the respective serum levels. Importantly, patients with PsA had significantly higher serum concentrations of S100A9, CP, VEGF, IL-6 and TNFα compared with patients with only Ps, but only S100A9 and CP could efficiently discriminate healthy individuals, patients with Ps and patients with PsA.ConclusionsKeratinocyte-derived S100A9 plays a regulatory role in psoriatic skin and joint disease. In humans, S100A9/CP is a promising marker that could help in identifying patients with Ps at risk of developing PsA.

Journal Title
Annals of the Rheumatic Diseases
Citation
Annals of the Rheumatic Diseases (2022).<https://ard.bmj.com/content/early/2022/07/04/annrheumdis-2022-222229>
Zugehörige ORCIDs